文献速递炎症性肠病

炎症性肠病的费用及保险延迟的经济影响

The Costs of Inflammatory Bowel Disease and the Financial Impact of Insurance Delays.
PubMed 文献 · Am J Gastroenterol · 2026-02-27

综述总结炎症性肠病(IBD)的相关费用,评估事先授权(PA)流程延迟和行政流程如何增加直接与间接经济负担,并识别可降低儿童和成人IBD总体费用的策略。

要点

  • IBD需长期治疗,先进疗法费用高,PA流程复杂且不标准化。
  • 保险相关治疗延迟与不良临床结局和缺勤增加相关。
  • PA拒绝常导致使用缺乏临床获益证据的非优选药物。

核心结论

  • IBD相关费用高昂,PA流程延迟和行政负担增加直接与间接费用,需策略降低总体费用。

研究设计与样本

  • 综述,总结IBD相关费用并评估PA流程及行政流程对费用负担的影响。

主要发现

  • 先进疗法因研发和制造复杂而费用高昂,导致广泛实施复杂且非标准化的PA流程。
  • 保险公司间政策异质性、覆盖排除和标准程序差异使PA导航费力、费钱、耗时,且不总带来一致有利结果或覆盖。
  • 保险相关治疗延迟与不良临床结局和缺勤增加相关。
  • PA拒绝常导致使用缺乏临床获益证据的非优选药物。

临床怎么用

  • 临床需关注PA流程延迟对IBD患者结局和费用的影响,并探索降低总体费用的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inflammatory bowel diseases (IBDs) are chronic gastrointestinal disorders with systemic manifestations for which highly effective therapies and better understanding of treatment targets have transformed patient care. Owing to the low mortality and frequent early onset, as well as increasing prevalence of IBD, most patients are living with their disease for decades. Presently, proactive use of treat-to-target approaches aimed at endoscopic outcomes and integration of steroid-sparing advanced therapies have become a cornerstone of IBD management, with the intent to optimize patient outcomes and achieve remission. However, the substantial costs tied to research, development, and intricate manufacturing have resulted in advanced therapies being costly, leading to widespread implementation of a complex and nonstandardized prior authorization (PA) process. The heterogeneity in policies, coverage exclusions, and standard procedures across insurers makes the PA navigation process labor-intensive, costly, and time-consuming, and does not always result in consistent favorable outcomes or coverage for patients. In addition, insurer-related treatment delays have been associated with adverse clinical outcomes and increased absenteeism. Furthermore, PA denials often lead to the use of nonpreferred agents lacking evidence of clinical benefit. This review will attempt to summarize the costs related to IBD, assess how delays related to the PA process and administrative processes contribute to both direct and indirect cost burdens, and identify strategies that can potentially reduce overall costs in both pediatric and adult IBD care.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Bhat S, Falaiye T, Moses J, et al. The Costs of Inflammatory Bowel Disease and the Financial Impact of Insurance Delays. Am J Gastroenterol. 2026. PMID: 41757781. doi:10.14309/ajg.0000000000003975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。